Equity Profile

SNN

Smith & Nephew plc

Health CareHealth Care Equipment$12.6B

Feb6Thu

Pre-Earnings Brief

UpcomingQ3-2019Pre-Market9:00 AM EST

Company Snapshot

Smith & Nephew plc (SNN) is a global medical technology company that specializes in advanced wound management, orthopedic reconstruction, and sports medicine. As a player in the health care equipment sector, its innovations are crucial for improving patient outcomes and reducing healthcare costs.

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if the company can maintain or improve its revenue growth, which is vital for sustaining market confidence.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SNN Q3-2019 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+19.92%

Avg Stock Reaction

+0.05%

Last Quarter Recap

In the last quarter, Smith & Nephew reported an EPS of $0.92, which was in line with expectations. The stock saw a modest increase of 1.23% the following day, indicating a generally positive market reaction.

Management Promises & Guidance

Focus on innovation in wound management products.
Commitment to expanding market presence in emerging markets.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue growth and profitability. The stock's implied volatility suggests that the market anticipates significant movement following the earnings report.

Bull Case

If the company reports strong revenue growth and improved margins, it could signal a robust recovery and innovation in key product lines, boosting investor confidence.

Bear Case

Conversely, any signs of declining market share or disappointing earnings could lead to a sell-off, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate in the wound management segment?

This will indicate how well the company is performing in a key area of its business and whether it can sustain its market position.

How is the company addressing competitive pressures in orthopedics?

Understanding the company's strategy in response to competition will be critical for assessing future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth in emerging markets, which could offset any challenges in developed regions.

Supporting Evidence

The company's recent investments in innovation could lead to stronger-than-expected sales.

Options pricing suggests a higher volatility than historical averages, indicating potential for a significant move.

Past performance shows that the stock has reacted positively to innovation announcements.

Key Risk

If the company reports a significant increase in market share in emerging markets, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around the company's ability to innovate and maintain its competitive edge in a challenging market.

Bull Confirmed If

A revenue growth rate of over 5% in the wound management segment would confirm the bull case.

Bear Confirmed If

A decline in market share in key segments would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±32.33%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±32.3% while SNN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

28.2%

Calls (300)P/C Ratio: 0.10Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Smith & Nephew beats expectations, history suggests the stock could rise by around 2.38% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience minimal movement as investors digest the information.

Miss

A miss could lead to a decline of approximately 1.11%, as seen in previous quarters, reflecting disappointment in performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in wound management.
2Details on market share changes in orthopedics.
3Insights into cost management strategies.
4Any commentary on geographic revenue performance.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Kennametal Inc.

Company Snapshot

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if the company can maintain or improve its revenue growth, which is vital for sustaining market confidence.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SNN Q3-2019 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+19.92%

Avg Stock Reaction

+0.05%

Last Quarter Recap

Management Promises & Guidance

Focus on innovation in wound management products.
Commitment to expanding market presence in emerging markets.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Bull Case

If the company reports strong revenue growth and improved margins, it could signal a robust recovery and innovation in key product lines, boosting investor confidence.

Bear Case

Conversely, any signs of declining market share or disappointing earnings could lead to a sell-off, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate in the wound management segment?

This will indicate how well the company is performing in a key area of its business and whether it can sustain its market position.

How is the company addressing competitive pressures in orthopedics?

Understanding the company's strategy in response to competition will be critical for assessing future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth in emerging markets, which could offset any challenges in developed regions.

Supporting Evidence

The company's recent investments in innovation could lead to stronger-than-expected sales.

Options pricing suggests a higher volatility than historical averages, indicating potential for a significant move.

Past performance shows that the stock has reacted positively to innovation announcements.

Key Risk

If the company reports a significant increase in market share in emerging markets, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around the company's ability to innovate and maintain its competitive edge in a challenging market.

Bull Confirmed If

A revenue growth rate of over 5% in the wound management segment would confirm the bull case.

Bear Confirmed If

A decline in market share in key segments would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±32.33%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±32.3% while SNN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

28.2%

Calls (300)P/C Ratio: 0.10Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Smith & Nephew beats expectations, history suggests the stock could rise by around 2.38% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience minimal movement as investors digest the information.

Miss

A miss could lead to a decline of approximately 1.11%, as seen in previous quarters, reflecting disappointment in performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in wound management.
2Details on market share changes in orthopedics.
3Insights into cost management strategies.
4Any commentary on geographic revenue performance.
5Future guidance on revenue expectations.